Clinical Trials Logo

Filter by:
NCT ID: NCT06254690 Recruiting - Breast Cancer Clinical Trials

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

Evaluate the safety and efficacy of Pyrotinib in the transition from low-dose to normal-dose regimen for HER2-positive advanced first-line breast cancer

NCT ID: NCT06254560 Recruiting - Clinical trials for Severe Aplastic Anemia

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Start date: February 23, 2023
Phase: Phase 2
Study type: Interventional

Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR. Due to the lack of effective intervention methods, patients with PTR suffer increased platelet transfusions, bleeding events and treatment costs, prolonged hospital stays, and decreased survival rate. SAA with PTR has become a challenge for physicians. The experiment aims to explore the efficacy of rituximab in the treatment of SAA with PTR, and establish a new effective, safe treatment method with relatively low treatment cost.

NCT ID: NCT06254521 Recruiting - Rectal Cancer Clinical Trials

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Start date: February 22, 2024
Phase: Phase 2
Study type: Interventional

This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced MSS rectal cancer.

NCT ID: NCT06254508 Recruiting - Obesity Clinical Trials

Online Exercise Program and Dietary Advice (FITT-online) for Children and Adolescents With Obesity

FITT-online
Start date: February 22, 2024
Phase: N/A
Study type: Interventional

This controlled clinical trial aims to compare the effects of an online program that includes exercise guided by the FITT-VP principle and dietary advice, conducted by fitness coaches, in children and adolescents with obesity with a control group that will be enrolled in conventional in-clinic nutrition and exercise advice. All participants will be monitored for 8 months during the active intervention, and followed by 16 months of observation. The study will evaluate the following parameters between groups: BMI, anthropometry, blood biochemistry panel (ALT/AST, lipids, uric acid, HOMA-IR, HbA1c), food frequency questionaire, household survey, satisfaction survey, and adverse events.

NCT ID: NCT06254443 Recruiting - Clinical trials for Acute Lower Gastrointestinal Bleeding

Oral PEG vs. Enema in Urgent Colonoscopy for ALGIB

CANDLE
Start date: January 8, 2024
Phase: N/A
Study type: Interventional

The main goal of this study is to assess whether the diagnostic efficacy of enema is non-inferior to that of oral polyethylene glycol (PEG) in acute lower gastrointestinal bleeding (ALGIB) patients requiring urgent colonoscopy. The secondary objectives include: 1) evaluating potential differences between the enema and oral PEG groups in terms of the difficulty and safety of colonoscopy, as well as exacerbation of bleeding; 2) conducting subgroup analyses to compare the effectiveness of the two bowel preparation methods in specific populations, exploring potential candidate groups for different bowel preparation strategies, and promoting individualized diagnosis and treatment for ALGIB.

NCT ID: NCT06254274 Recruiting - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

A Study of RAY1225 in Participants With Type 2 Diabetes

Start date: February 26, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

NCT ID: NCT06254261 Recruiting - Obesity Clinical Trials

A Study of RAY1225 in Participants With Obesity

Start date: February 21, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

NCT ID: NCT06253975 Recruiting - Wound Heal Clinical Trials

Randomized, Controlled, Multicenter Study of Extracellular Vesicles From Human Adipose Tissue Promoting Wound Healing

Start date: February 15, 2024
Phase: N/A
Study type: Interventional

By randomly assigning study subjects into groups, interventions with adipose tissue-derived extracellular vesicles (AT-EVs) and placebos are conducted to evaluate whether AT-EVs can promote effective healing of recalcitrant wounds.

NCT ID: NCT06253962 Recruiting - Clinical trials for Carotid Atherosclerosis

Carotid Atherosclerosis in Predicting Coronary Artery Disease

CACA
Start date: February 10, 2024
Phase:
Study type: Observational

Carotid plaque burden and composition features, particularly lipid necrotic core, are significantly associated with severity of CAD stenosis. This study aims to explore the relationship between various phenotypic patterns of carotid atherosclerosis with the prevalence, phenotype, and severity of coronary atherosclerosis. The patients with chest tightness or chest pain will receive carotid artery ultrasonography before coronary angiography so as to explore the relationship between them.

NCT ID: NCT06253546 Recruiting - Schizophrenia Clinical Trials

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Start date: March 28, 2024
Phase: Phase 1
Study type: Interventional

Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia. Secondary Objectives: - To evaluate the pharmacokinetics (PK) of single doses of TV-44749 administered sc. - To evaluate the pharmacokinetics of oral olanzapine tablets following multiple dose administration. - To monitor the safety and tolerability of multiple doses of oral olanzapine tablets given in the study.